Navigation Links
Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx
Date:3/7/2012

said Brett Monia, Ph.D., Senior Vice President, Drug Discovery and Corporate Development at Isis.  "We are very excited about the potential of our Generation 2.5 STAT3 drug to treat human cancers with high unmet medical needs as we continue to be the leader in antisense innovation. The advancement of our first drug incorporating our new, more potent Generation 2.5 chemistry is a key milestone and should allow us to further extend the reach of our technology into new targets, new tissues, and new disease opportunities."

ISIS-STAT3Rx is the first Generation 2.5 drug in Isis' pipeline. It is designed to treat cancer by inhibiting the production of STAT3, a gene that blocks natural cell death and that is critical for tumor cell growth and survival.  Inhibition of STAT3 has been shown to block the induction of tumor-associated cytokines involved in the progression of cancer, such as IL-6, IL-1, TGFβ, and IL-10, which could serve as important biomarkers in clinical studies.  Analyses of these cytokines in Phase 1 could serve as an early indicator of anticancer activity of ISIS-STAT3Rx in patients with cancer.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regardin
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Initiates Plans for China Office
2. American Regent Initiates Nationwide Voluntary Recall of Phenylephrine HCl Injection, USP, 1%, 5 mL Vial, Lot# 0693, Due to Visible Particles
3. Echo Therapeutics Initiates Clinical Trials of its Symphony tCGM System in Critical Care Patients
4. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
6. Sumagen Initiates Clinical Testing of Omnia Biologics Manufactured HIV Vaccine
7. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
8. Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program
9. Isis Initiates Phase 1 Clinical Study of ISIS-SMNRx in Patients With Spinal Muscular Atrophy
10. Soligenix Initiates Next Generation Anthrax Vaccine Development Program Under Agreement With Harvard University
11. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015 ExeGi Pharma, ... and probiotic treatments, announced today that it has been ... and Non-prescription Health Products Directorate (NNHPD) to sell Visbiome™ ... Visbiome was developed by Professor Claudio De Simone ... extensive clinical investigation. Professor De Simone recently signed an ...
(Date:7/1/2015)... 2015 Boston Scientific Corporation (NYSE: BSX ) ... highlights for the second quarter ended June 30, 2015 on ... The call will be hosted by Mike Mahoney , ... executive vice president and chief financial officer. A ... the Boston Scientific website. Webcast registration is available on the ...
(Date:7/1/2015)... Fla. , July 1, 2015 Rock ... development company focused on chronic inflammatory disease and neurologic ... of principle study with anatabine citrate, the Company,s lead ... oral dose of anatabine citrate can significantly inhibit the ... subjects. The Company is developing this compound in a ...
Breaking Medicine Technology:ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3Boston Scientific To Webcast Second Quarter 2015 Earnings Call On July 23 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 2Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 3Rock Creek Pharmaceuticals Reports Human Proof of Principle Study of Lead Compound Demonstrating Inhibition of Inflammatory Markers In White Blood Cells 4
(Date:7/1/2015)... ... July 01, 2015 , ... Dr. Surya Challa of ... 6th on WAVY-TV’s The Hampton Roads Show to discuss non-invasive CoolSculpting . On ... exercise fall short. , CoolSculpting fat reduction utilizes Cryolipolysis to literally freeze stubborn, ...
(Date:7/1/2015)... ... 01, 2015 , ... During the first week of June, ... and Development) and Chuck Corso (Associate Sales Trainer) participated in the 44th Annual ... together learning and development professionals from more than 300 life sciences companies around ...
(Date:7/1/2015)... ... July 01, 2015 , ... Convoy of Hope will partner with ... Cities on Saturday, August 1, at Spring Lake Park High School. , During the ... $1 million worth of goods and services including free food, health services, family portraits, ...
(Date:7/1/2015)... TEXAS (PRWEB) , ... July 01, 2015 , ... ... and solution provider of IBM software products, announced today that it has received ... for the integration, display and detailed analysis of data from multiple sources providing ...
(Date:7/1/2015)... , ... July 01, 2015 , ... Amada Senior Care, ... new office in the greater Phoenix area – their Mesa, Arizona location . ... senior care with their purchase of the rights to the area after years of ...
Breaking Medicine News(10 mins):Health News:Dr. Surya Challa of Chesapeake Vein Center and MedSpa Will be Featured on The Hampton Roads Show on WAVY-TV 2Health News:Dr. Surya Challa of Chesapeake Vein Center and MedSpa Will be Featured on The Hampton Roads Show on WAVY-TV 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 2Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 4Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 2Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 3Health News:Element Blue Receives Trademark Protection from U.S. Patent and Trademark Office for Its Award Winning SensorInsight® Software 4Health News:Amada Senior Care Expands to Greater Phoenix Area 2
... Ten Years of Service, BETHESDA, Md., Dec. 7 ... certain risk factors -- such as parental stress,maternal depression ... a new 10-year study released today by the Family ... who participated in,FSA,s Healthy Families Montgomery program over the ...
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... the consumer and professional markets, announced,today that it ... Healthcare,Conference being held December 12, 2007 at The ... Executive Officer, and Jon Russell, Vice,President, Finance, will ...
... and ... Now Even More Heart Benefits, HORSHAM, Pa., ... NutriSystem Advanced, the company,s,breakthrough weight-loss and health and wellness platform. ... a complete,program that includes new proprietary ingredient blends to support ...
... Risks for Obese Youth Increases Urgency for Helping ... Families Make their Holidays ,Heart Healthy, CHICAGO, Dec. ... England Journal of Medicine indicates overweight and obesity in,childhood and ... serious consequences of our nation,s obesity,epidemic are yet to come. ...
... Former CEO Agrees to Forego $420 Million in Compensation ... and Chairman,of UnitedHealth Group Corporation, Dr. William McGuire, today ... that call,for McGuire to return more than $420 million ... to the dating of stock options during,his tenure as ...
... Longs Drugs in ... Honolulu, WALNUT CREEK, Calif., ... announce today that it plans,to lease space to Access Medical Clinics to own ... 2007. The Longs Drugs in,the Mililani Town Center and Ewa Beach will soon ...
Cached Medicine News:Health News:County-Wide Home Visiting Program Found to Reduce Child Abuse and Neglect 2Health News:County-Wide Home Visiting Program Found to Reduce Child Abuse and Neglect 3Health News:Inverness Medical Innovations to Participate at 2007 RBC Healthcare Conference on December 12, 2007 2Health News:NutriSystem 'Advances' Weight-Loss Category 2Health News:NutriSystem 'Advances' Weight-Loss Category 3Health News:YMCA of the USA Offers Simple Tips to Give the Lifetime Gift of Health and Well-Being to Family and Friends This Holiday Season 2Health News:YMCA of the USA Offers Simple Tips to Give the Lifetime Gift of Health and Well-Being to Family and Friends This Holiday Season 3Health News:YMCA of the USA Offers Simple Tips to Give the Lifetime Gift of Health and Well-Being to Family and Friends This Holiday Season 4Health News:Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 2Health News:Dr. William McGuire Settles with the SEC and the UnitedHealth Group Special Litigation Committee on Stock Options Matter 3Health News:Longs Drugs Plans to Become the First Retailer in Hawaii With Walk-in Medical Clinics 2Health News:Longs Drugs Plans to Become the First Retailer in Hawaii With Walk-in Medical Clinics 3
The new ProteomeX Workstation enables the rapid set up, execution and analysis of multidimensional LC/MS methods, providing you with the best possible technique to characterize your complex proteomic...
... over a wide range of concentration, ... more thorough characterization than other methods. ... relative change in the distribution of ... to measure heterogeneity, stoichiometry and self-associating ...
Storage temperature: 2 - 8C, linearity: 0 - 700 mg/dL, expected values: 30 - 780 mg/dL. Available with calibrator and number of tests 110....
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint, reaction is complete in five minutes at 37C. Wavelength: 540 nm. Linearity: 1000 mg/dL (11.3 mmol/...
Medicine Products: